What is the primary purpose of this 10-K filing for investors?

The primary purpose of this 10-K filing is to provide investors with a comprehensive overview of Eli Lilly & Co.'s financial performance, operational results, and business activities for the fiscal year ended December 30, 1993. It serves as a key document for understanding the company's financial health, its market position, and any significant developments or risks.

What specific financial information can investors find in a 10-K filing?

A 10-K filing typically includes audited financial statements (balance sheets, income statements, cash flow statements), management's discussion and analysis of financial condition and results of operations, detailed notes to the financial statements, information about the company's products and services, its competitive landscape, legal proceedings, and risk factors.

Since the full report content is not available, what is the significance of the directory listing?

The directory listing confirms that Eli Lilly & Co. has officially submitted its 10-K filing to the SEC. While it doesn't provide the actual data, it's a necessary step for regulatory compliance and makes the full report accessible to investors through the SEC's EDGAR system.

Where can I find the actual content of the 1993 10-K for Eli Lilly & Co.?

To access the full content of the 1993 10-K filing for Eli Lilly & Co., you would typically search the SEC's EDGAR database using the company's ticker symbol (LLY) and the filing date or form type. The provided directory listing, if it were the actual report, would be the source.

LLY 10-K FY1993 Annual Report — Revenue, Net Income, EPS

Summary

Eli Lilly & Co. (LLY) filed its 10-K for the fiscal year ending December 30, 1993, on March 24, 1994. While the provided text is a directory listing of the filing and not the full report content, it indicates the company is providing its annual financial and operational overview to the SEC. Investors would typically look to this filing for detailed financial statements, management's discussion and analysis of financial condition and results of operations, and information on the company's products, market position, and future outlook. Given the absence of specific financial figures and narrative from the actual report, a comprehensive analysis of LLY's performance, strategic initiatives, or risk factors for 1993 is not possible based solely on this directory. However, the filing itself signifies LLY's compliance with regulatory requirements and its commitment to transparency with shareholders. Investors should seek the full 10-K document to understand the company's financial health, revenue drivers, and any potential challenges or growth opportunities identified by management during that period.

Key Highlights

1Eli Lilly & Co. (LLY) filed its annual 10-K report for the fiscal year ending December 30, 1993.
2The filing date was March 24, 1994, as per SEC requirements.
3The provided text is a directory listing of the filing, not the full report content.
4This filing is a crucial document for investors to assess the company's financial performance and strategic position.
5Investors would typically expect detailed financial statements, operational reviews, and forward-looking information within the complete 10-K.
6The filing demonstrates LLY's adherence to regulatory disclosure standards.

ELI LILLY & Co Annual Report, Year Ended Dec 31, 1993

Summary

Key Highlights

Frequently Asked Questions